Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...

Protagenic Therapeutics (NASDAQ: PTIX) just pulled off a biotech plot twist worthy of a season finale. On May 19, shares ...

We recently showed that phase-pure molybdenum carbide nanotubes can be durable supports for platinum (Pt) nanoparticles in hydrogen evolution reaction (HER). In this paper we further characterize ...

Preliminary PT-112 Phase 2 clinical outcomes in metastatic castration-resistant prostate cancer patients will be presented at the ASCO 2025 Annual Meeting NEW YORK, May 20, 2025 /PRNewswire ...

Promontory Therapeutics will initiate a phase 3 trial of PT-112 for mCRPC following a positive FDA meeting. PT-112 induces immunogenic cancer cell death and targets bone disease sites, with ...

Kawai and Lee (1997) investigated the influence on membrane formation of different solvents in the casting solution. The phase diagrams of the systems were obtained by determining the equilibrium ...

† Key Laboratory of Polymer Chemistry & Physics of Ministry of Education, Center for Soft Matter Science and Engineering, College of Chemistry and Molecular Engineering, Peking University, Beijing ...